Efimosfermin alfa clinical trials
How each study uses efimosfermin alfa is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the efimosfermin alfa studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2026 (5)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2025 | 2 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test efimosfermin alfa.
- Oct 2027A Study of Efimosfermin Alfa in Adults With Hepatic ImpairmentPhase 1 · GlaxoSmithKline
Studies
Open first, then newest update. How each study uses efimosfermin alfa is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Study of Efimosfermin Alfa in Adults With Hepatic ImpairmentRecruitingPhase 1GlaxoSmithKlineNCT07358546Written as Efimosfermin alfa
- A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)RecruitingPhase 3GlaxoSmithKlineNCT07701993Written as Efimosfermin alfa
- A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)RecruitingPhase 3GlaxoSmithKlineNCT07704892Written as Efimosfermin alfa
- A Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult Participants With Alcohol-related Liver Disease (ALD)RecruitingPhase 2GlaxoSmithKlineNCT07791043Written as Efimosfermin alfa
- A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASHRecruitingPhase 3GlaxoSmithKlineNCT07221188Written as Efimosfermin Alfa
- A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASHRecruitingPhase 3GlaxoSmithKlineNCT07221227Written as Efimosfermin alfa
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and White/European AncestryCompletedPhase 1GlaxoSmithKlineNCT07335198Written as Efimosfermin alfa
- Safety Study of LLF580 in Obese VolunteersCompletedPhase 1Novartis PharmaceuticalsNCT03466203Written as LLF580
Codes
What other systems call efimosfermin alfa · ClinicalTrials.gg INT002197
- MeSH (NLM) C000732024efimosfermin alfaOne source NLM
- UNII (FDA) Y114QW0F16EFIMOSFERMIN ALFAConfirmed FDA, NLM
- NCI Thesaurus C206904Efimosfermin AlfaOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000732024 | efimosfermin alfa | One source NLM |
| UNII (FDA) | Y114QW0F16 | EFIMOSFERMIN ALFA | Confirmed FDA, NLM |
| NCI Thesaurus | C206904 | Efimosfermin Alfa | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.